DAPA HF: Dapagliflozin Offers New HF Therapy, Even Sans Diabetes

The diabetes drug dapagliflozin (Farxiga, AstraZeneca) provides substantial benefits among patients with chronic heart failure with reduced ejection fraction (HFrEF) -even in those without diabetes, according to the DAPA HF trial.

The sodium-glucose cotransporter 2 (SGLT2) inhibitor reduced the relative risk for the primary outcome – a composite of time to first cardiovascular (CV) death or HF hospitalization or urgent HF visit requiring intravenous therapy -by 26% when added to standard therapy, compared with standard care alone (hazard ratio [HR], 0.74; 95% CI, 0.65 – 0.85; P = .00001). The number needed to treat was 21. Dapagliflozin reduced the risk for all-cause death by 17% (HR, 0.83; 95% CI, 0.71 – 0.97) and patient-reported HF symptoms, without an increase in adverse events.

DAPA HF is considered a landmark study showing the benefits of the use of SGLT2 inhibitors in heart failure patients, which has been documented in EMPA-REG OUTCOME and CANVAS, however, this study was only performed on diabetics.



Theo https://www.medscape.com/viewartic


Xem thêm

Kiểm soát đường huyết nhanh chóng trong giai đoạn đầu của bệnh đái tháo đường để có kết quả tốt nhất.

Theo UKPDS điều quan trọng là phải xác định những người mắc đái tháo đường …